Internal medicine

Pathology

Receptor

Cancer

Oncology

Biopsy

Lung

Lung cancer

Chemotherapy

Pleural effusion

Etoposide

Cisplatin

Carboplatin

Adenocarcinoma of the lung

Adenocarcinoma

Tyrosine kinase

Cancer research

Medicine

Clinical Lung Cancer

The majority of resistance to Rearranged during transfection (RET)-specific tyrosine kinase inhibitors (TKI) described in RET-rearranged non-small cell lung cancer (NSCLC) patients are driven by RET-independent mechanisms. We provide the first case report of a RET-rearranged lung adenocarcinoma (LUAD) transformation into small-cell lung cancer (SCLC) as a mechanism of acquired resistance to pralsetinib. A 43-year-old patient presented with a RET-rearranged LUAD revealed by pleural effusion. After 14 months of response to pralsetinib, biopsy of a progressive pleural lesion found a phenotypic transformation into SCLC.

Small-Cell Lung Cancer Transformation as a Mechanism of Resistance to Pralsetinib in RET-Rearranged Lung Adenocarcinoma: A Case Report